201 related articles for article (PubMed ID: 24245549)
1. Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
van Heumen BW; Roelofs HM; te Morsche RH; Nagengast FM; Peters WH
Orphanet J Rare Dis; 2013 Nov; 8():181. PubMed ID: 24245549
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
3. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
4. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
van Heumen BW; Roelofs HM; Te Morsche RH; Marian B; Nagengast FM; Peters WH
Exp Cell Res; 2012 Apr; 318(7):819-27. PubMed ID: 22366264
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
7. Loss of extracellular E-cadherin in the normal mucosa of duodenum and colon of patients with familial adenomatous polyposis.
Berkhout M; Gosens MJ; Brouwer KM; Peters WH; Nagengast FM; van Krieken JH; Nagtegaal ID
Hum Pathol; 2006 Nov; 37(11):1389-99. PubMed ID: 16949915
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
9. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
11. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.
Huang K; Gutierrez LP; Bülow S; Gallinger S; Castells A; Eagle CJ; Church JM
Fam Cancer; 2011 Jun; 10(2):303-8. PubMed ID: 21359561
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression.
Jungck M; Grünhage F; Spengler U; Dernac A; Mathiak M; Caspari R; Friedl W; Sauerbruch T
Int J Colorectal Dis; 2004 Sep; 19(5):438-45. PubMed ID: 14986031
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
Pérez-Segura P; Bodas A; Sereno M; Martínez-Amores B; Olivera H; Díaz S; López-Asenjo JA; Puente J; Maluenda C; Díaz-Rubio E
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):230-2. PubMed ID: 20197018
[TBL] [Abstract][Full Text] [Related]
15. The effect of ursodesoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial.
Parc Y; Desaint B; Fléjou JF; Lefèvre JH; Serfaty L; Vienne A; Kotti S; Simon T; Tiret E
Colorectal Dis; 2012 Jul; 14(7):854-60. PubMed ID: 21899713
[TBL] [Abstract][Full Text] [Related]
16. Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?
Di Leo A; Nesi G; Principi M; Piscitelli D; Girardi B; Pricci M; Losurdo G; Iannone A; Ierardi E; Tonelli F
World J Gastroenterol; 2016 Mar; 22(11):3202-11. PubMed ID: 27003997
[TBL] [Abstract][Full Text] [Related]
17. Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis.
Berkhout M; Roelofs HM; te Morsche RH; Dekker E; van Krieken JH; Nagengast FM; Peters WH
Br J Surg; 2008 Apr; 95(4):499-505. PubMed ID: 18161889
[TBL] [Abstract][Full Text] [Related]
18. Familial adenomatous polyposis.
Half E; Bercovich D; Rozen P
Orphanet J Rare Dis; 2009 Oct; 4():22. PubMed ID: 19822006
[TBL] [Abstract][Full Text] [Related]
19. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis.
Thiruvengadam SS; OʼMalley M; LaGuardia L; Lopez R; Wang Z; Shadrach BL; Chen Y; Li C; Veigl ML; Barnholtz-Sloan JS; Pai RK; Church JM; Kalady MF; Walsh RM; Burke CA
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00053. PubMed ID: 31211760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
